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ABSTRACT 
Background. Recent studies have shown that production of cortisol not only takes place 
in several non-adrenal peripheral tissues such as epithelial cells but, also, the local inter-
conversion between cortisone and cortisol is regulated by the 11β-hydroxysteroid 
dehydrogenases (11-HSDs). However, little is known about the activity of this non-
adrenal glucocorticoid system in cancers.  
Methods. The presence of a functioning glucocorticoid system was assessed in human skin 
squamous cell carcinoma (SCC) and melanoma and further, in 16 epithelial cell lines from 
8 different tissue types using ELISA, Western blotting and immunofluorescence. 11β-
HSD2 was inhibited both pharmacologically and by siRNA technology. Naïve CD8+ T 
cells were used to test the paracrine effects of cancer-derived cortisol on the immune 
system in vitro. Functional assays included cell-cell adhesion and cohesion in two- and 
three-dimensional models. Immunohistochemical data of 11-HSD expression were 
generated using tissue microarrays of 40 cases of human squamous cell carcinomas as well 
as a database featuring 315 cancer cases from 15 different tissues.  
Results. We show that cortisol production is a common feature of malignant cells and has 
paracrine functions. Cortisol production correlated with the magnitude of glucocorticoid 
receptor (GR)-dependent inhibition of tumour-specific CD8+ T cells in vitro. 11β-HSDs, 
were detectable in human skin SCCs and melanoma. Analyses of publicly available protein 
expression data of 11β-HSDs demonstrated that 11β-HSD1 and -HSD2 were dysregulated 
in the majority (73%), of malignancies. Pharmacological manipulation of 11β-HSD2 
activity by 18βGlycyrrhetinic Acid (GA) and silencing by specific siRNAs modulated the 
bioavailability of cortisol. Cortisol also acted in an autocrine manner and promoted cell 
invasion in vitro and cell-cell adhesion and cohesion in two- and three-dimensional models. 
Immunohistochemical analyses using tissue microarrays showed that expression of 11β-
HSD2 was significantly reduced in human SCCs of the skin.  
Conclusion. The results demonstrate evidence of a cancer-associated glucocorticoid 
system and show for the first time, the functional significance of cancer-derived cortisol in 
tumour progression.  
Keywords: cancer, cortisol, lymphocytes, 11-HSDs, keratinocytes, cell adhesion 
Introduction 
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Glucocorticoids (GC) are important lipid hormones that are involved in the regulation of 
stress responses, metabolism and immune homeostasis (Sapolsky et al., 2000). Whilst the 
adrenal glands are the major source of GC, it is now recognized that GC synthesis occurs 
at other sites (Noti et al., 2009) such as the thymus (Vacchio et al., 1994), brain 
(MacKenzie et al., 2000; Davies & MacKenzie, 2003), prostate gland (Herr and 
Pfitzenmaier, 2006), vascular endothelium (Takeda et al., 1994), intestinal epithelium 
(Sidler et al., 2011) and epidermis (Slominski & Wortsman, 2000; Hannen et al., 2011). In 
the skin, steroidogenesis is involved in the modulation of a variety of physiological 
functions (Slominski et al., 2000; Vukelic et al., 2011; Kennedy et al., 2015). Recently, we 
characterized the oral glucocorticoid system in detail and showed that the local 
concentration of active cortisol in normal keratinocytes had the capacity to modulate 
disease progression in conditions where steroids are used routinely as a treatment modality 
(Cirillo & Prime, 2011; Cirillo et al., 2012). These findings raise the possibility that 
steroidogenesis may also play a key role in carcinogenesis, possibly through autocrine and 
paracrine mechanisms. Given the known immunomodulatory function of cortisol, we 
wished to examine whether local non-adrenal steroids had the capacity to modulate anti-
cancer immune responses.   
Regulation of neuroendocrine function occurs primarily through the control of the 
production and degradation of steroid hormones (Slominski & Wortsman, 2000). 
Activation of the steroid cortisone to cortisol occurs via 11β-hydroxysteroid 
dehydrogenase (HSD) 1 (HSD11B1 gene; Tomlinson et al., 2004) whereas the reverse, 
cortisol to cortisone, involves 11β-HSD2 (HSD11B2 gene; Ma et al., 2011). 11β-HSDs, 
therefore, are key enzymes in the tissue-specific regulation of glucocorticoids and current 
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thinking suggests that their deregulation is associated with a variety of pathological 
processes in the skin (Vukelic et al., 2011; Hannen et al., 2011, Cirillo et al., 2012). Whilst 
the role of 11β-HSD1 is well documented in epidermal physiology (Terao et al., 2011; 
Tiganescu et al., 2011; Lee et al., 2013; Itoi et al., 2013; Terao et al., 2014; Tiganescu et 
al., 2015), little is known about the role of 11β-HSD2 in skin keratinocytes. Clarification 
of the function of 11β-HSD2 in epidermal keratinocytes may have major clinical 
implications because of the therapeutic relevance of corticosteroid agents in the 
management of many skin disorders (Jackson et al. 2007). 
 
In the present study, we assessed cortisol production in a broad spectrum of cell and tissue 
types. We show that cortisol levels correlated with inhibition of proliferation amongst 
tumour-specific CD8+ T lymphocytes. Using immunohistochemical analysis of cancer 
samples, we demonstrated alterations of 11β-HSD enzymes in a large number of tissue 
types, including skin SCC. The role of 11β-HSD2 in normal and malignant keratinocytes 
was also investigated using functional assays of metabolism, adhesion and scattering from 
three-dimensional aggregates. The data demonstrate for the first time that 11β-HSD2 plays 
a key role in the pathophysiology of malignant epidermal cells.  
 
 
Materials and methods 
Antibodies and chemicals  
Antibodies against residues 261-405 of human 11β-HSD2 (clone H-145), and amino acids 
65-164 of 11β-HSD1 (clone H-100), anti-tubulin, horseradish peroxidase (HRP)-
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conjugated and FITC-conjugated anti-rabbit IgGs and 18β-Glycyrrhetinic acid (18β-GA) 
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Nitrocellulose 
membranes, keratinocyte growth medium and antibiotics/anti-mycotics were obtained 
from Invitrogen (Paisley, UK). Reagents for enhanced chemiluminescence and films were 
obtained from Amersham Biosciences (Buckinghamshire, UK) and the reagents for protein 
extraction and cell culture were obtained from Sigma (Sigma-Aldrich, Gillingham, Dorset, 
UK). 
 
Cells and culture conditions 
A broad spectrum (n=16), of normal and malignant cell lines from 8 different tissue types 
were used in this study including prostate (DU145, PC3, VCaP, LNCaP), bladder (T24, 
RT4), breast (MCF-7), colorectal (HT29, SW620, SWH80), renal (mouse RenCA WT) and 
pancreas (HUp-T3; a kind gift from Professor Chris Paraskeva, School of Cellular and 
Molecular Medicine, University of Bristol, UK). These cells were validated using 
karyotypic analysis prior to use. These cells retained their phenotype and function, together 
with their growth characteristics in vitro, throughout the 3 months that they were routinely 
kept in continuous culture. HaCaT cells are a strain of immortalized human skin 
keratinocytes that have an active steroid metabolism (Cirillo and Prime, 2011) and display 
normal differentiation in vivo (Boukamp et al., 1988; Milewich et al., 1988). HaCaT c-Ha-
ras-transfected clones (I-7, II-3, and RT-3; Fusenig and Boukamp, 1998) were kind gifts 
from Professor Norbert Fusenig (DKFZ, Heidelberg, Germany). Following subcutaneous 
transplantation to athymic mice, HaCaT cells are non-tumorigenic, I-7 cells form non-
invasive epidermoid cysts, II-3 cells form primary SCCs with minimal metastatic 
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dissemination and RT-3 cells, the most aggressive cell type, form large SCCs at the site of 
inoculation and have widespread metastatic dissemination (Fusening and Boukamp, 1998). 
The cells are widely used as a model of epidermal cancer progression (Davies et al., 2006) 
and were last authenticated prior to commencing the experiments in 2012 with mRNA 
microarrays. The oral SCC cell strain (H357) underwent full genome sequencing in 2016 
whereas the skin SCC cell line A431 was purchased from Sigma Aldrich.   
All of the cell lines/strains were derived prior to 2001 and therefore, were not subject to 
Ethical Committee approval in the UK. The cells were placed in serum-free DMEM/F12 
for 24 hours before the collection of supernatants for cortisol assessment; RT-3 was 
cultured in media containing 400mg/ml geneticin sulphate (G418; PAA laboratories, UK). 
At the time of experimentation, cells were seeded in 35-mm Petri plastic dishes and grown 
to confluence. Cells were grown in a humidified atmosphere of 5% CO2/air at 37°C.   Ethics 
committee approvals were was obtained for this study both in Bristol (E5133) and in 
Melbourne (1340716.1), and high standards of ethics was applied in carrying out all of the 
investigations.  
 
Multicellular aggregates (MCAs) were prepared according to published protocols (Kantak 
and Kramer, 1998). To generate MCAs, cell monolayers were first treated with EDTA to 
prepare single cell suspensions and then, the cells were seeded onto polyhydroxylethyl-
methacrylate (poly-HEMA)-coated 60-mm dishes (6 × 105 cells/dish) in the presence of 
serum-free DMEM for 12 hours, with or without 0.5% (w/v) 18β-Glycyrrhetinic Acid (GA). 
Unlike malignant keratinocytes (Kantak & Kramer, 1998), the culture of normal 
keratinocytes for prolonged periods (e.g. 24 hours) in the absence of extracellular cell 
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matrix (ECM) attachment resulted in significant cell death and non-viable MCAs (data not 
shown).  
 
Tumour specific CD8+ T lymphocyte proliferation in vitro.  
Using anti-CD8 MACS midiMACS (Miltenyi Biotec, Bisley, UK), single-cell suspensions 
of peripheral lymph node and spleen cells from CL4 TcR–transgenic mice were enriched 
for naïve CD8+ T lymphocytes that recognized a tumor specific antigen (Jenkinson  et al., 
2005).  Anti-CD3 monoclonal antibody (10µg/ml) was added to triplicate wells of 96-well 
rounded plates in a total volume of 50µl 1xPBS and incubated in a 5% vol./vol. CO2 
humidified atmosphere at 370C for 1.5 hours; control wells contained 1xPBS only. Plates 
were washed three times with 300µl 1x PBS. In certain experiments, cortisol (10-
1000ng/ml) was added to the wells.  5 × 104 purified naïve, CL4, CD8+ T lymphocytes 
were added to each well and were cultured in a 5% vol./vol. CO2 humidified atmosphere 
at 370C for 72 hours and pulsed with 1µCi/well 3H-thymidine (Amersham Life Sciences) 
in 25µl serum-free culture media for the last 8 hours. Cells were harvested on fiber filters 
(Filtermats; COX Scientific Ltd., Kettering, UK) using a 24-well harvester (Skatron, Flow 
Laboratories, Oslo, Norway). Fiber filters were then dried and sealed into bags with 3ml 
Betaplate Scint (Wallac-Oy, (Wallac Oy, Turku, Finland). 3H-thymidine incorporation was 
read by a 1450 Microbeta liquid scintillation counter for windows 2.7 (Wallac Oy, Turku, 
Finland). Data were analysed using Microsoft Office Excel and Prism 4.03 software 
(Graphpad). 
siRNA transfection experiments 
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11β-HSD-directed siRNA pools and the negative-control pool were transfected as 
described previously (Cirillo et al., 2011). The efficiency of transfection was monitored by 
Western blotting (WB) of 11β-HSD1/2 expression. 
 
Western blotting  
For the assessment of protein levels, WB on whole-cell lysates and in-cell WB on culture 
monolayers was undertaken using standard procedures (Cirillo et al., 2010). For all WB, a 
1:500 dilution was used for the primary antibodies and the species-specific secondary IgG 
was diluted to 1:5000.  
 
Enzyme-linked immunosorbent assay (ELISA) 
For quantification of cortisol levels with conventional ELISA, the conditioned media were 
collected at time points specified in the Results. Cortisol concentrations were measured 
with a Cortisol Parameter Assay Kit (R&D Systems, Minneapolis, MN, USA) and 
quantified at 415 nm with the ELx808 Microplate Reader (BioTek Instruments, Inc., 
Winooski, VT, USA). 
 
Immunohistochemistry 
Skin tissue microarrays (Cat. No. SK483, multiple skin squamous cell carcinoma tissue 
arrays; US Biomax, Rockville, MD, USA) and formalin-fixed, paraffin-embedded skin 
biopsies from individuals with squamous cell carcinoma, melanoma, and without skin 
disease were subjected to immunohistochemical analyses, as described previously 
(Ricketts et al., 1998; Lanza et al., 2008). Following antigen retrieval, the primary antibody 
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to 11β-HSD1 and 11β-HSD2 was used at a 1:100 and 1:50 dilution, respectively, and the 
species-specific secondary IgG was diluted to 1:5000. The primary antibody was withheld 
from negative controls and these were incubated in diluent alone. Staining was quantified 
following the criteria detailed by Yao et al. (2007). Normal and tumour sections were 
scored independently by two investigators (SSP and NC) and graded as no (0), weak (1), 
moderate (2), or strong (3) staining. 
 
Database search  
A publicly available repository (http://www.proteinatlas.org) was used to access 
immunohistochemical data of 11β-HSDs staining, as reported in Supplementary Table I.  
GENT (http://medicalgenome.kribb.re.kr/GENT), a Gene Expression across Normal 
and Tumour tissue database, was used to interrogate mRNA expression in both cell lines 
and tissues. 
 
Immunofluorescence microscopy  
Immunofluorescence microscopy was performed as previously described (Cirillo et al., 
2007), but with minor modifications. Briefly, cells were cultured in 4-well-plates (Nunc™ 
Cell-Culture Treated Multidishes, Thermo Fisher Scientific, Fisher Scientific UK Ltd.), in 
standard conditions. At 60% confluence, cells were fixed with 100% vol./vol. ice-cold 
methanol for 10 minutes at 4°C and then incubated with 0.5 μg/ml Hoetstch staining 
(H6024, Sigma-Aldrich) for 30 minutes at 4°C and then blocked with 5% wt/vol. BSA-
PBS solution at 4°C for 60 minutes. Samples were incubated overnight at 4°C with anti-
11β-HSD1/2 primary antibody at 1/100 dilution in 2% BSA-PBS followed by FITC-
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conjugated species-specific IgG for 1 hour at 1/1000 dilution in 2% wt/vol. BSA-PBS. All 
intermediate washing steps were performed with PBS. Images were taken with a 
fluorescence microscope (EVOS™ FLoid™ Cell Imaging Station, Life technologies). 
 
Adhesion and cohesion assays in 2- and 3-dimensional models  
To quantify the strength of 2-D cell-to-cell adhesion in monolayers, we undertook dispase-
based cell dissociation assays, as described previously (Calautti et al., 1998).  
For 3-D cohesion assays, MCAs were first analysed by phase-contrast microscopy to check 
for their compact appearance. Then, the MCAs were sedimented in 15ml tubes and 
subjected to mechanical stress by pipetting 20 times with a 5ml pipette. The residual 
spheroids were sedimented at 1G and the ratio of the number of MCA-forming cells and 
the number of single cells in suspension was calculated. The ratio of total to single cells 
was indicative of intercellular adhesive strength (Cirillo & Boutros, 2008).  
 
For scattering assays, the surface (pixels) covered by cells originating from disaggregating 
MCAs were measured and then those values were normalized against the total number of 
cells. 
 
Statistical analysis 
The statistical significance of the data was evaluated by the Student’s t test. Data are 
reported as mean ± standard deviation and differences were considered to be significant 
when p was <0.05. 
 
Results 
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Tumour-derived cortisol  inhibits lymphocyte proliferation 
We and others have shown that tumour-specific CD8+ T lymphocyte activity is suppressed 
by factors produced within the tumour microenvironment (Ahmadi et al., 2008; Janicki et 
al., 2008; Basingab et al., 2016). To test whether the production of cortisol by tumour cells 
had paracrine effects that could target tumour specific immune responses, we exposed 
naïve tumour-specific CD8+ T lymphocytes (CL4 cells) to conditioned media from 
cortisol-producing II-3 malignant epidermal cells (Cirillo et al., 2012; Kennedy et al., 
2015) stimulated with ACTH and, in parallel, treated lymphocytes with hydrocortisone. 
The data showed that the rate of proliferation of CL4 CD8+ T lymphocytes was 
significantly reduced in the presence of conditioned media from ACTH-stimulated II-3 
cells; the effect was inhibited in the presence of the GR inhibitor RU486 thereby 
confirming that such inhibition was specific to cortisol (Figure 1A). In control experiments 
we confirmed that hydrocortisone directly inhibited the rate of proliferation amongst naïve 
mouse tumour-specific CD8+ T cells primed in vitro using plate-bound anti-CD3 and anti 
CD28 mAb in a dose-dependent manner (Supplementary Figure 1). We extended these 
observations to examine whether unstimulated malignant cells from other tissue-types 
synthesized cortisol de novo and, if so, whether conditioned media from these same cells 
could inhibit naïve tumour-specific CD8+ T lymphocyte proliferation. All (12/12) of the 
malignant cell lines from the prostate, bladder, breast, colorectum, kidney and pancreas 
(Supplementary Figure 2A), produced detectable levels of cortisol (0.1-8.4 ng/ml) at 
baseline; 11 of 12 reduced the proliferation rate of CD8+ T lymphocytes and one cell line 
from bladder cancer (T24) increased the proliferation (Supplementary Figure 1). Cell 
lines of colorectal origin (HT29, SW620, SWH80) produced little, if any, cortisol but 
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caused marked inhibition of proliferation (Figure 1B) suggesting that there may be other 
mechanisms of immune suppression/regulation exhibited by this cell type (see Discussion). 
When the data relating to the colorectal lines were excluded, there was a strong correlation 
between basal cortisol production and inhibition of lymphocyte proliferation (Spearman’s 
correlation coefficient was 0.89; Figure 1C). Collectively, the data demonstrate that a large 
variety of cancer cells from different tissues produce active cortisol and inhibit tumour 
specific CD8+ T lymphocyte proliferation in vitro. 
 
Cortisol interconversion is modulated by 11β-hydroxysteroid dehydrogenases 
The above experiments demonstrated that the production of basal levels of cortisol was  
common in tumour cells. Next, we wanted to test whether the interconversion of cortisol 
could be modulated locally and, to this end, we used  HaCaT skin keratinocytes and their 
mutant c-Ha-ras-transfected clones (Figure 1A).  All clones consistently secreted cortisol 
under basal conditions and increased steroid production following stimulation with ACTH; 
c-Ha-ras-transfected clones that formed malignant squamous cell carcinomas following 
transplantation to athymic mice (II-3, RT-3) produced significantly more cortisol following 
ACTH stimulation than their non-tumorigenic counterparts (HaCaT) and c-Ha-ras-
transfected clones that formed benign epidermoid cysts on transplantation to athymic mice 
(I-7). Other SCC cells derived from tumour samples were also investigated and were found 
to secrete cortisol under basal conditions (Supplementary Figure 3).  
 
Previous studies demonstrated that HaCaT expressed active 11β-HSD1 and 11β-HSD2 
enzymes (Cirillo et al., 2011, Kennedy et al., 2015). In this study, we extended these 
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observations and demonstrated that benign (I-7) and malignant (II-3, RT-3) c-Ha-ras clones 
also expressed functional 11β-HSD1 and 11β-HSD2 (Figure 2B-D). Silencing of 11β-
HSD1 correlated with a reduced ability of malignant cells to convert cortisone to active 
cortisol; this was progressively restored by an increase of 11β-HSD1 expression (Figure 
2C). Similarly, 11β-HSD2 controlled the inactivation of cortisol in a dose-dependent 
fashion (Figure 2D). 11β-HSD1 and 11β-HSD2 were also expressed in SCCs (n=10) and 
melanomas (n=10) (Figure 2E, F). Taken together, the data demonstrate that skin cancer 
cells have the capacity to regulate cortisol levels through the expression of 11β-HSD1 and 
11β-HSD2.  
 
Expression of 11β-HSD enzymes is altered in cancers  
To investigate whether the enzymes modulating the local concentration of active steroid 
were dysregulated in malignancy, we examined the expression of 11-HSD1/2 in normal 
and malignant tissues using publicly available datasets. According to GENT datasets, 
mRNA levels encodying for 11-HSD1 (HSD11B1) and 11-HSD2 (HSD11B2) differed 
in normal and neoplastic tissues. Therefore, we examined the expression profile of these 
enzymes at the protein level using Protein Atlas (http: //www.proteinatlas.org). Fifteen 
normal tissue types (n = 126; controls) were matched with their malignant counterparts (n 
= 315; cancers); a total of 441 different samples were examined in which there were 590 
cancer specimens (Supplementary Table I). 12 of 15 (80%) cancer types had significant 
changes (p<0.05) of 11-HSDs staining (Figure 3). In the main, there was an inverse 
relationship in the pattern of expression of 11-HSD1 and 11-HSD2, with either an 
increase in 11-HSD1 staining (cervical, glial, urotelial) or decreased expression of 11-
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HSD2 (colon, lung, stomach, thyroid), or both (endometrial, head and neck, renal, prostate). 
11-HSD1 was also upregulated in liver cancer with a p value close to significance (50% 
overall increase compared to control tissue, p = 0.069). Exceptions to the above 
generalisation included breast and pancreatic cancers which did not show major changes 
compared to matched normal tissues and cancer of the testis which showed increased 11-
HSD2 levels. Collectively, these results strongly suggest that dysregulation of the enzymes 
associated with local cortisol interconversion is a common feature of solid tumours. 
 
Local cortisol levels regulate keratinocyte invasion, cohesion, and scattering in a two- and 
three-dimensional models of epidermal cancer 
We hypothesized that the local production and degradation of cortisol could influence 
tumour progression. First, we demonstrated that cortisone, cortisol (hydrocortisone when 
used as a medication) and ACTH acted directly to increase the invasion of epidermal 
keratinocytes (Figure 4A-D). The effect was most striking amongst II-3 cells where there 
was a statistical increase in invasion following treatment with hydrocortisone and ACTH. 
The effect was not seen in HaCaT, I-7 or RT-3 cells.  
Hydrocortisone has been shown to exert pro-adhesive effects in normal keratinocytes 
(Nguyen et al., 2004). As inhibition of 11-HSD2 leads to increased cortisol levels in the 
culture medium, a dispase-based assay was undertaken to investigate whether inhibition of 
11-HSD2 altered intercellular adhesion in malignant epidermal cells. For this experiment 
we opted for a pharmacological block of the enzyme using 18β-GA because this inhibitor, 
unlike siRNAs, allowed to achieve consistent levels of 11-HSD2 activity throughout the 
experimental period (not shown). As shown in Figure 5A-C, keratinocyte monolayers 
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displayed increased cell–cell adhesive strength (i.e., resistance to cell–cell detachment) in 
the presence of the 11-HSD2 inhibitor 18-GA. 11β-HSD2 activity was also examined in 
a three-dimensional model of cell adhesion. Multicellular aggregates were prepared in the 
presence or absence of 18β-GA (Figure 5D, E) and whilst the number of cells that 
aggregated together in suspension and formed MCAs after 24 hours of incubation was 
similar in both groups (not shown), intercellular cohesion of mature (24 hour) MCAs, as 
quantified by the release of single cells from the spheroids after mechanical stress, was 
higher in MCAs cultured in the presence of 18β-GA (Figure 5H). The MCAs were left to 
attach and disaggregate on a collagen substrate in 18β-GA-free medium and migration 
from the core of the cell aggregate was measured in a scattering assay. Control MCAs were 
almost entirely dissolved 6 hours after seeding (Figure 5F) whereas MCAs grown in the 
presence of 18β-GA displayed a reduced ability to scatter and migrate from the spheroids 
after attachment on collagen substrates (Figure 5G) and were able to cover only ~55% of 
the area compared to control MCAs (Figure 5I). 
  
Taken together, the data demonstrate that pharmacological modulation of cortisol 
degradation via 11β-HSD2 inhibition influences cell adhesion and three-dimensional 
intercellular cohesion of malignant keratinocytes.  
 
Expression of 11β-HSD2 in skin and its down-regulation in squamous cell carcinoma 
The above results suggested that 11β-HSD2 expression was important to the bioavailability 
of tumour-derived cortisol. However, previous research on the expression of 11β-HSD2 in 
the human integument has given conflicting results (Tiganescu et al. 2011, Vukelic et al. 
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2011, Terao et al. 2013). In this study, we used a rabbit antibody against the residues 261-
405 of human 11β-HSD2 at a 1:100 dilution, a concentration at which normal skin 
displayed strong staining (Supplementary Figure 4). Using tissue arrays, 
immunohistochemical expression of 11β-HSD2 was examined in 40 cases of squamous 
cell carcinoma (SCC) and 8 normal skin controls (Figure 6). The intensity of 11β-HSD2 
staining in the malignant tissues was consistently less than control tissues. 11 of 40 SCCs 
(27.5%) displayed no staining whilst staining intensity was weak to moderate in a further 
25 samples (62.5%). Overall, the 11β-HSD2 staining score in SCC was statistically less 
(p<0.05) than in the controls (Supplementary Figure 5). We therefore conclude that the 
expression of 11β-HSD2, a key enzyme in the local control of keratinocyte-derived cortisol, 
is significantly reduced in SCCs of the skin.  
Taken together, the data demonstrate that cancer cells produce cortisol irrespective of their 
tissue of origin. Furthermore, 11β-HSD2-mediated regulation of tumour-derived cortisol  
potentially plays an important role in the pathobiology of epidermal malignancy.  
 
Discussion 
This study presents a series of observations that demonstrate an important role for the 
glucocorticoid system, and specifically for 11β-HSD2, in the physiology of normal and 
malignant epithelial cells. First, we show that cortisol production is a common feature of a 
broad spectrum of cancers and that cancer-derived cortisol inhibits CD8+ cytotoxic T 
lymphocyte proliferation in a GR-specific fashion. Second, we demonstrate that 11β-
HSD1/2 expression is altered in many different cancer types in a fashion that is predicted 
to lead to a pro cortisol-producing phenotype. Third, we establish that normal human skin 
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tissues express detectable levels of 11β-HSD2 and that levels are reduced in SCCs. Fourth, 
we demonstrate in vitro that 11β-HSD2 is synthesized by human malignant keratinocytes 
under basal conditions and its expression and activity regulate both the production and 
inter-conversion of active cortisol.  Finally, we show that 11β-HSD2 modulates 
intercellular adhesion and that inhibition of 11β-HSD2 by 18β-GA increases intercellular 
cohesion. .  
 
A major finding of this study was that cancer cells produce cortisol regardless of their tissue 
of origin, strongly supporting the view that a cancer-associated glucocorticoid system is 
active in malignancy. Not only was cortisol production enhanced by ACTH treatment but 
also, analysis of CD8+ T cell responses revealed a linear correlation between basal cortisol 
levels in supernatants from cancer cells and inhibition of lymphocyte proliferation. Given 
the importance of T cell-mediated responses in the progression of cancer, as well as its 
prognostic relevance (Knutson & Disis, 2005; Ward et al., 2014), our data suggest that the 
production of cortisol by malignant cells may have an important immunoregulatory 
function. These findings are consistent with Sidler et al. (2011) who showed that tumour-
derived GCs from colon cancer induced suppression of T-cell activation. The present study, 
however, is the first to extend this concept to a broad spectrum of solid tumours. It is also 
intriguing that under our experimental conditions, colorectal cancer cells (HT29, SW620, 
SWH80) were the only cell type not to show a correlation between cortisol production and 
inhibition of CD8 T lymphocytes. Specifically, these cells produced low amounts of basal 
cortisol but concurrently, reduced T cell proliferation. We have shown previously that other 
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tumour-derived molecules such as prostaglandins may be involved in the immune 
regulation of CD8 cells in cancer. (Ahmadi et al., 2008; Basingab et al., 2016). 
 
In the past two decades, the intracellular inter-conversion of inactive and active steroids by 
the 11β-HSDs has emerged as a key mechanism underlying tissue-specific regulation of 
glucocorticoid action. In non-adrenal tissues, 11β-HSDs have been shown to play a crucial 
role in the control of basic physiological functions, as well as in disease processes such as 
osteoporosis (Cooper et al. 2008), insulin-resistance (Purnell et al. 2009), chronic 
periodontitis (Nakata et al. 2016) and cancer (Zhang et al., 2009; Rabbitt et al. 2003). With 
regard to squamous epithelia, a number of studies from Slominski’s group have supported 
the hypothesis that the skin has the potential to act as a neuroendocrine organ (Slominski 
et al. 2006; 2007; 2011). We have extended these observations and demonstrated that 
squamous epithelium lining the oral cavity acts as a corticosteroid-producing system and 
that alteration of 11β-HSDs in oral keratinocytes may play an important role in disease 
(Cirillo et al. 2012). However, while studies addressing the function of 11β-HSDs in 
epidermal tissues support a key role for 11β-HSD type 1 in epidermal biology and 
pathophysiology (Hardy et al. 2006; Hennebert et al. 2007; Terao et al. 2011; Tiganescu 
et al. 2011, Lee et al. 2013, Itoi et al. 2013, Terao et al. 2014, Tiganescu et al. 2015), there 
is some disagreement about the putative expression and function of 11β-HSD type 2 
(Cirillo and Prime, 2011; Vukelic et al. 2011; Tiganescu et al. 2011, Terao et al. 2013). In 
the reports by Tiganescu et al. (2009) and Terao et al. (2013), for example, the expression 
of 11β-HSD2 could not be demonstrated in human skin suggesting that keratinocytes 
cannot de-activate cortisol. In the present study, we demonstrated 11β-HSD2 in normal 
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skin specimens, findings that are consistent with our published data showing 11β-HSD2 at 
both the mRNA and protein levels in keratinocytes. We conclude that 11β-HSD2 is present 
in epidermal keratinocytes. 
  
To the best of our knowledge, the data reported in the present study are the first to show 
that 11β-HSD2 is not only expressed by epidermal keratinocytes but, also, that the 
pharmacological manipulation of 11β-HSD2 modulates cortisol levels and regulates 
certain cellular functions. The question remains, however, as to whether 11β-HSD2 can be 
modified for therapeutic benefit. Interestingly, it has been shown recently that 18β-GA, 
administered either prophylactically or therapeutically, induces a dramatic reduction in 
bone loss using a mouse model of periodontitis (Sasaki et al., 2010). The authors suggested 
that this effect was independent of glucocorticoids because a down-regulation of 11β-
HSD2 mRNA was not seen. 18β-GA, however, is known to impair 11β-HSD2 function by 
blocking enzymatic activity rather than by inducing down-regulation at the transcriptional 
level (Zhang et al. 2009; Kratschmar et al. 2011). In view of our recent findings (Cirillo et 
al., 2012), we tentatively suggest that 18β-GA may reduce tissue inflammation and limit 
the bone loss that occurs in periodontal disease by increasing local cortisol levels.  Further 
studies, however, are required to verify this proposal..  
 
Our data demonstrate that silencing of 11β-HSD1 correlates with a temporary decrease in 
the local bioavailability of active cortisol, which increases once 11β-HSD1 expression is 
restored. The reverse is true for 11β-HSD2 where expression of the enzyme inversely 
correlates with cortisol levels. Therefore, alteration of 11β-HSD1/2 expression and 
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function is tightly linked to the levels of cortisol in the microenvironment. In the present 
study, we examined the expression of 11β-HSD enzymes in a broad spectrum of cancer-
types using an open IHC database. We show that dysregulation of 11β-HSDs is common 
in a broad spectrum of cancer-types; the enzymes were either up-regulated (11β-HSD1) or 
down-regulated (11β-HSD2), or both, in 11 out of 15 cancer types from 315 cases; the 
trend was consistent with an increase in the bioavailability of local cortisol. In SCC of the 
skin, there was a significant down-regulation of 11β-HSD2 compared to normal skin., 
findings that are in accord with results from colorectal  (Žbánková et al., 2004) and oral 
(Cirillo et al., 2012) cancers, but contrast with osteosarcoma (Bland et al., 1999) and 
ovarian cancer (Temkin et al., 2006). The subject has recently been extensively reviewed  
(Azher et al., 2016).  
 
Recently, it has been shown that corticosteroids suppress key components of the 
senescence-associated secretory phenotype (SASP) (Laberge et al., 2012). In epithelial 
cells, cellular senescence is a mechanism that suppresses the early stages of cancer 
development suggesting that tumour-derived cortisol may inhibit the anti-cancer activity 
of the SASP and favour cancer progression. By contrast, we have shown that the SASP of 
cancer-associated fibroblasts (CAFs) exerts pro-tumorigenic paracrine effects on 
malignant oral epithelial cells (Hassona et al., 2013; 2014). In these circumstances, cortisol 
produced by malignant epithelial cells would be expected to have paracrine tumour 
suppressive effects. Interestingly, our recent observations have shown that  cortisol is 
produced by normal fibroblasts (Cirillo et al., 2012) as well as cancer associated fibroblasts 
(Cirillo N, unpublished observations). Studies are on-going to investigate the role of 
 21 
cortisol in the tumour micro-environment and the inter-relationship between epithelial cells, 
fibroblasts and immune cells.  
 
In conclusion, we report that a non-adrenal glucocorticoid system is active in cancer and 
that the resulting cortisol production suppresses lymphocyte proliferation. Further, we 
show that 11β-HSD2 modulates intercellular cohesion and that inhibition of 11β-HSD2 
leads to an increase of secreted cortisol in epidermal cells. 11β-HSD2 is down-regulated in 
SCCs of the skin as well as in 8 other cancer types. We suggest that 11β-HSD2 could be 
used as a potential biomarker of tumour progression and may be of value therapeutically 
by regulating local tissue concentrations of cortisol in skin disease. 
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Legend to figures 
 
Figure 1. Naïve TcR transgenic tumour antigen-specific CL4 CD8+ T lymphocytes were 
incubated for 24 hours with supernatants of ACTH-treated II-3 cells in the presence the 
GR inhibitor RU486, or without treatment (A).  CD8+ lymphocytes were incubated with 
supernatants from 12 cancer cells with known basal cortisol production. The cells were 
counted after 24 hours and their number was plotted against the corresponding cortisol 
levels in the supernatants (B,C).   
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Figure 2. Cortisol levels in the supernatant of un-stimulated cells (Bsl) and cells treated 
with 10nM ACTH for 24 hours (ACTH) were assessed by ELISA (A). Western blotting 
and immunofluorescence were undertaken to investigate the expression of 11-HSD1 and 
11-HSD2 proteins (B). siRNA was used to transiently knock-down the expression of 11-
HSD1 (C) and 11-HSD2 (D) in II-3 cells; in parallel, the protein level of these enzymes 
was assessed by Western blotting. Silencing of 11-HSD1 resulted in a reduced ability of 
II-3 to activate cortisone (100nM) into cortisol (C). Silencing of 11-HSD2 in HC-treated 
cells (100nM) resulted in an increase in the concentration of active cortisol in supernatants 
(D). Both effects were transient and progressively reverted when the expression levels of 
11-HSDs were restored. Both enzymes were detectable by IHC in human skin cancers, 
namely SCC (E) and melanoma (F).  
 
Figure 3. Staining intensity of 11-HSD1/2 using a publicly available dataset featuring 15 
different normal/malignant tissues was computed and illustrated by histogram. p value of 
paired t test is reported. Blue colour indicates up-regulation whereas red colour indicates 
down-regulation. 
 
 
Figure 4. HaCaT (A), I-7 (B), II-3 (C), and RT-3 (D) were used for the invasion assay in 
the presence of 100nM cortisone, 100nM hydrocortisone, 10nM ACTH or without 
treatment (Control). ANOVA statistical analysis was used to determine the significance of 
the results. The histograms show mean values of four independent experiments ± standard 
deviation.  
 
Figure 5. A dispase-based assay was undertaken to assess cell-cell adhesion strength in II-
3 cells with or without treatment with 18β-Glycyrrhetinic Acid (A-C). Cohesion strength 
(D, E, H) and scattering (F, G, I) of 3-D cellular aggregates in the presence or absence of 
18β-GA was also assessed. 
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Figure 6. Staining of 11-HSD2 at a 1:100 dilution was undertaken using tissue 
microarrays. The array is shown with (a) and without (b) IHC staining and shows cases of 
squamous cell carcinoma (n=40), normal skin tissues (n=8) and a positive control 
(melanoma). Typical aspects of normal (c, e) and cancerous (d, f) samples are reported at 
4x and 20x magnification.  
 
 
 
